Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2005_107 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose) | Drug | |||
| Placebo / Duration of Treatment: 2 days for screening period | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Mean of total sleep time over 2 nights. |
| Measure | Description | Time Frame |
|---|---|---|
| Mean of other PSG sleep parameters over 2 nights, mean of subjective sleep parameters, and exploratory residual effect. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007319 | Sleep Initiation and Maintenance Disorders |
| ID | Term |
|---|---|
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C015542 | gaboxadol |
| D000081206 | Duration of Therapy |
| ID | Term |
|---|---|
| D005791 | Patient Care |
| D013812 | Therapeutics |
| D006296 | Health Services |
| D005159 | Health Care Facilities Workforce and Services |
Not provided
Not provided